• British Pharmacopoeia Volume I & II
  • Monographs: Medicinal and Pharmaceutical Substances

Sulpiride

European Union chaplet of stars
scroll to previous hit
scroll to next hit
General Notices

(Ph Eur monograph 1045)

bp2010_v2_07_monographs_medicinal_and_pharmaceutical_substances sulpiride_1_2009_60_cs.png


C15H23N3O4S    341.4    15676-16-1

Action and use

Dopamine receptor antagonist; neuroleptic.

Preparation

Sulpiride Tablets

Ph Eur

DEFINITION

(RS)-N-[(1-Ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulphamoylbenzamide.

Content

98.5 per cent to 101.0 per cent (dried substance).

CHARACTERS
Appearance

White or almost white, crystalline powder.

Solubility

Practically insoluble in water, sparingly soluble in methanol, slightly soluble in ethanol (96 per cent) and in methylene chloride. It dissolves in dilute solutions of mineral acids and alkali hydroxides.

IDENTIFICATION

First identification  A, B.

Second identification  A, C, D.

A.  Melting point (2.2.14): 177 °C to 181 °C.

B.  Infrared absorption spectrophotometry (2.2.24).

Preparation  Discs.

Comparison  Sulpiride CRS.

C.  Examine the chromatograms obtained in test A for related substances.

Detection  Examine in ultraviolet light at 254 nm.

Results  The principal spot in the chromatogram obtained with test solution (b) is similar in position and size to the principal spot in the chromatogram obtained with reference solution (a).

D.  To about 1 mg in a porcelain dish, add 0.5 ml of sulphuric acid R and 0.05 ml of formaldehyde solution R. Examined in ultraviolet light at 365 nm, the solution shows blue fluorescence.

TESTS
Appearance of solution

The solution is clear (2.2.1) and not more intensely coloured than reference solution Y6 (2.2.2, Method I).

Dissolve 1.0 g in dilute acetic acid R and dilute to 10 ml with the same acid.

Related substances

A. Thin-layer chromatography (2.2.27).

Test solution (a)  Dissolve 0.20 g of the substance to be examined in methanol R and dilute to 10 ml with the same solvent. Sonicate until complete dissolution.

Test solution (b)  Dilute 1 ml of test solution (a) to 10 ml with methanol R.

Reference solution (a)  Dissolve 20 mg of sulpiride CRS in methanol R and dilute to 10 ml with the same solvent.

Reference solution (b)  Dissolve 5 mg of sulpiride impurity A CRS in methanol R and dilute to 25 ml with the same solvent.

Reference solution (c)  Dilute 1.0 ml of reference solution (b) to 10 ml with methanol R.

Plate  TLC silica gel F254 plate R.

Mobile phase  Concentrated ammonia R, dioxan R, methanol R, methylene chloride R (2:10:14:90 V/V/V/V).

Application  10 µl.

Development  Over a path of 10 cm.

Drying  In air.

Detection  Examine in ultraviolet light at 254 nm for identification test C and then spray with ninhydrin solution R; heat at 100-105 °C for 15 min and examine in daylight.

Limit  Test solution (a):

  • impurity A: any spot due to impurity A is not more intense than the corresponding spot in the chromatogram obtained with reference solution (c) (0.1 per cent).

B.  Liquid chromatography (2.2.29).

Test solution  Dissolve 0.100 g of the substance to be examined in the mobile phase and dilute to 100.0 ml with the mobile phase.

Reference solution (a)  Dilute 3.0 ml of the test solution to 100.0 ml with the mobile phase. Dilute 1.0 ml of this solution to 10.0 ml with the mobile phase.

Reference solution (b)  Dissolve 10 mg of sulpiride CRS and 10 mg of sulpiride impurity B CRS in the mobile phase and dilute to 100.0 ml with the mobile phase.

Column:
  • size: l  =  0.25 m, Ø  =  4.6 mm;

Mobile phase  Mix 10 volumes of acetonitrile R, 10 volumes of methanol R and 80 volumes of a solution containing 6.8 g/l of potassium dihydrogen phosphate R and 1 g/l of sodium octanesulphonate R, adjusted to pH 3.3 using phosphoric acid R.

Flow rate  1.5 ml/min.

Detection  Spectrophotometer at 240 nm.

Injection  10 µl.

Run time  2.5 times the retention time of sulpiride.

System suitability  Reference solution (b):

  • resolution: minimum 2.5 between the peaks due to impurity B and sulpiride.
Limit:
  • total: not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent).
Chlorides (2.4.4)

Maximum 100 ppm.

Shake 1.0 g with 20 ml of water R. Filter through a sintered-glass filter (40) (2.1.2). To 10 ml of the filtrate add 5 ml of water R.

Iron (2.4.9)

Maximum 10 ppm.

Ignite 1.0 g in a silica crucible. To the residue add 1 ml of 1 M hydrochloric acid, 3 ml of water R and 0.1 ml of nitric acid R. Heat on a water-bath for a few minutes. Place the solution in a test-tube. Rinse the crucible with 4 ml of water R. Collect the rinsings in the test-tube and dilute to 10 ml with water R.

Maximum 10 ppm.

1.0 g complies with test C. Prepare the reference solution using 1 ml of lead standard solution (10 ppm Pb) R.

Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

Maximum 0.1 per cent, determined on 1.0 g.

ASSAY

Dissolve 0.250 g in 80 ml of anhydrous acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).

1 ml of 0.1 M perchloric acid is equivalent to 34.14 mg of C15H23N3O4S.

IMPURITIES

Specified impurities  A.

Other detectable impurities  (The following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use): B, C, D, E, F, G.

bp2010_v2_07_monographs_medicinal_and_pharmaceutical_substances sulpiride_2_2009_60_cs.png


A.  [(2RS)-1-ethylpyrrolidin-2-yl]methanamine,

bp2010_v2_07_monographs_medicinal_and_pharmaceutical_substances sulpiride_3_2009_60_cs.png


B.  R  =  O-CH3: methyl 2-methoxy-5-sulphamoylbenzoate,

C.  R  =  O-C2H5: ethyl 2-methoxy-5-sulphamoylbenzoate,

D.  R  =  OH: 2-methoxy-5-sulphamoylbenzoic acid,

E.  R  =  NH2: 2-methoxy-5-sulphamoylbenzamide,

bp2010_v2_07_monographs_medicinal_and_pharmaceutical_substances sulpiride_4_2009_60_cs.png


F.  1-ethyl-2-[[(2-methoxy-5-sulphamoylbenzoyl)amino]methyl]pyrrolidine 1-oxide,

bp2010_v2_07_monographs_medicinal_and_pharmaceutical_substances sulpiride_5_2009_60_cs.png


G.  (RS)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-hydroxy-5-sulphamoylbenzamide.

Ph Eur